June 15, 2004

All about influence

It looks like Eliot Spitzer isn't the only one concerned about drug company non-disclosure of clinical trial data: now the International Committee of Medical Journal Editors is weighing a policy that would require pharmaceutical firms to publicly register the commencement of clinical trials in order to get the results published later. Apparently the editors of journals like the New England Journal of Medicine and JAMA don't appreciate being unpaid marketing agents for Big Pharma.

Also, the American Medical Association adopted a resolution supporting the establishment of a public registry today. It seems the docs and the journals agree that the worth of a study can only be judged in context--a context that Big Pharma tries to avoid when it might mean reduced revenues for them.

And just think about how much medical research we could fund with 286.9 million dollars.

Posted by Carey at June 15, 2004 08:58 PM